BioCentury | Sep 18, 2020
Product Development

Sept. 17 Quick Takes: Another Tecfidera setback for Biogen; plus ChemoCentryx PDUFA date and Amytrx’s debut

...vasculitis therapyChemoCentryx Inc. (NASDAQ:CCXI) said Thursday FDA has accepted the company’s NDA for avacopan, a C5a...
...Jacek Hawiger at Vanderbilt University and has raised $11 million in series A funding. TARGETSC5aComplement 5a BC...
BioCentury | Jun 19, 2020
Product Development

InflaRx, Kiniksa anti-inflammatory mAbs yield trend toward lower COVID-19 mortality, plus Sinopharm reports antibody readout from vaccine trial

...antibody tests. Both tests have already been granted an EUA from FDA. Targets C5a - Complement 5a...
...Editor mavrilimumab (cam-3001) CaCP29, IFX-1 InflaRx N.V. Kiniksa Pharmaceuticals Ltd. China National Pharmaceutical Group Corp. (Sinopharm) Chembio Diagnostics Inc. Ortho Clinical Diagnostics Inc. Complement 5a (C5a) Granulocyte...
BioCentury | Apr 21, 2020
Product Development

Trio of tactics to target COVID-19 hyperinflammation

...of Soliris. According to BioCentury’s Resource Center , two companies have started clinical testing of C5a...
BioCentury | Apr 1, 2020
Product Development

Chinese data propel InflaRx anti-complement mAb into clinic for severe COVID-19 pneumonia

...has dosed the first patient in a randomized clinical trial of IFX-1, a mAb against C5a...
...mice. The viruses’ N proteins also potentiated lipopolysaccharide (LPS)-induced pneumonia in mice. Targets C5a - Complement 5a...
...Complement 5a MASP2 - Mannan binding lectin serine peptidase 2 (MASP2) Sandi Wong, Assistant Editor CaCP29, IFX-1 InflaRx N.V. Complement 5a (C5a) COVID-19 SARS-CoV-2 SARS-CoV-2...
BioCentury | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

...in all cases, the cascade converges on C5, which is cleaved into C5a and C5b. C5a...
BioCentury | Jun 29, 2019
Finance

Biotech backs down in 2Q19

...92% to $82 million. On June 5, the company announced IFX-1, an anti-human complement factor C5a...
...Food and Drug Administration (FDA), Silver Spring, Md. Targets Bruton's tyrosine kinase (BTK) C5a - Complement 5a...
BioCentury | Jun 5, 2019
Clinical News

InflaRx stumbles after C5a mAb fails in inflammatory skin disease study

...to severe hidradenitis suppurativa. In the 179-patient study, four different doses of the mAb against C5a...
...Phase IIa trial in 12 patients (see "InflaRx Reports Phase IIa Data of mAb Against C5a...
...in 2020 from the Phase IIb AURORA study to treat hidradenitis suppurativa. Targets: C5a - complement 5a...
BioCentury | Apr 19, 2019
Targets & Mechanisms

The next wave in neurodegeneration expands beyond neurons

...candidate ALS-205 inhibits C5a by blocking its receptor, C5AR1 (see “Complementary ALS Play” ). When C5a...
BioCentury | May 11, 2018
Financial News

InflaRx raises $51M follow-on

...Morgan, Leerink, BMO Capital Markets and SunTrust Robinson Humphrey. InflaRx's IFX-1 (CaCP29), a mAb against complement 5a (C5a)...
...treat rare inflammatory skin disease hidradenitis suppurativa (HS). InflaRx N.V. (NASDAQ:IFRX), Jena, Germany Chris Lieu CaCP29, IFX-1 InflaRx N.V. Complement 5a (C5a) Acne...
BioCentury | May 11, 2018
Finance

Amplifying oligos

...dosing cycles are the norm, such as cancer. Aptarion is developing a preclinical aptamer targeting C5a...
...Mass. Targets AGO2 - Argonaute RISC catalytic component 2 APOB-100 - Apolipoprotein B-100 C5a - Complement 5a...
...Inc. Roche Sanofi The Medicines Co. Valeant Pharmaceuticals International Inc. Wave Life Sciences Ltd. Apolipoprotein B-100 (APOB-100) Argonaute RISC catalytic component 2 (AGO2) Complement 5a (C5a) Platelet...
Items per page:
1 - 10 of 90